Canadian Cancer Trials Group Bulletins

General


Citations: MA.31 and CEC1

MA31 secondary analysis online publication

Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar W, Shepherd L, Gelmon K, Nielsen T. Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic her2-positive breast cancer: A secondary analysis of a randomized clinical trial (ONLINE). JAMA Oncology e172085, 2017.

http://jamanetwork.com/journals/jamaoncology/fullarticle/2645850

Citation for a CEC1 journal article

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rud?, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (ONLINE). The Lancet 2017.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31442-3/fulltext
Summary webpage:
http://www.ascopost.com/News/57954?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=6942251